AKTUALNIE REKRUTUJĄCE BADANIA
Badania prowadzone są w ośrodkach badań klinicznych PRATIA
Szpiczak plazmocytowy MM
NAZWA BADANIA
OPIS BADANIA
OŚRODKI PROWADZĄCE
NAZWA BADANIA
OPIS BADANIA
Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-9)
NAZWA BADANIA
OPIS BADANIA
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant (MagnetisMM-7)
NAZWA BADANIA
OPIS BADANIA
GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies
NAZWA BADANIA
OPIS BADANIA
MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (MAGNETISMM-5)
NAZWA BADANIA
OPIS BADANIA
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment (MonumenTAL-3)
NAZWA BADANIA
OPIS BADANIA
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135), Daratumumab, and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant (MagnetisMM-6)
W tym obszarze czytaj więcej:
Menu
